

# Tuberculosis profile: Ethiopia

Population 2019: 112 million

## Estimates of TB burden\*, 2019

	Number	(Rate per 100 000 population)
Total TB incidence	157 000 (110 000-211 000)	140 (98-188)
HIV-positive TB incidence	10 000 (7 100-14 000)	9.1 (6.4-12)
MDR/RR-TB incidence**	1 400 (970-2 000)	1.3 (0.87-1.8)
HIV-negative TB mortality	21 000 (14 000-31 000)	19 (12-28)
HIV-positive TB mortality	2 800 (1 900-3 800)	2.5 (1.7-3.4)

## Estimated proportion of TB cases with MDR/RR-TB\*, 2019

New cases	0.71% (0.62-0.8)
Previously treated cases	12% (11-13)

## Universal health coverage and social protection\*


TB treatment coverage (notified/estimated incidence), 2019	71% (53-100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2019	16% (9-24)

## TB case notifications, 2019

Total new and relapse	111 039
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	83%
- % pulmonary	70%
- % bacteriologically confirmed ^	63%
- % children aged 0-14 years	9%


## Incidence, New and relapse TB cases notified, HIV-positive TB incidence

(Rate per 100 000 population per year)



## HIV-negative TB mortality

(Rate per 100 000 population per year)



## Incidence, Notified cases by age group and sex, 2019

(Number)

- % women	40%
- % men	51%
Total cases notified	112 597

## TB/HIV care in new and relapse TB patients, 2019

	Number	(%)
Patients with known HIV status who are HIV-positive	5 978	6.5%
- on antiretroviral therapy	5 825	97%

## Drug-resistant TB care, 2019


% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^	36%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^	85%
Laboratory-confirmed cases - MDR/RR-TB ^^	658
Patients started on treatment - MDR/RR-TB ^^	658
Laboratory-confirmed cases - XDR-TB ^^	1
Patients started on treatment - XDR-TB ^^	4
MDR/RR-TB cases tested for resistance to any fluoroquinolone	418

## Treatment success rate and cohort size


	Success	Cohort
New cases registered in 2018	88%	110 189
Previously treated cases registered in 2018		
HIV-positive TB cases registered in 2018		
MDR/RR-TB cases started on second-line treatment in 2017	75%	708
XDR-TB cases started on second-line treatment in 2017	75%	4

## TB preventive treatment, 2019


% of HIV-positive people (newly enrolled in care) on preventive treatment	
---	--



## Treatment success rate



## Total budget



% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	33% (30-36)
---	----------------

## TB financing

National TB budget, 2020 (US\$ millions)	85
- Funding source, domestic	11%
- Funding source, international	33%
- unfunded	56%

\* Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.

\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

^ Calculated for pulmonary cases only

^^ Includes cases with unknown previous TB treatment history

^^^ Includes patients diagnosed before 2019 and patients who were not laboratory-confirmed

---

Generated 2020-10-15 by the World Health Organization (<https://www.who.int/tb/data/>)